Citi: Hospira's Investor Day Recap

Citi released a research report on Hospira

announcing its Investor Day recap. In the report, Citi writes, “CEO Mike Ball's strategy to accelerate up-front spending as part of revised LT guidance should help nudge Street EPS to more reasonable levels for 2012. While this helps to remove a layer of uncertainty, shares lack a catalyst to drive significant upside and investors are likely to remain skeptical on higher spending.” Citi has a Hold rating and a $49.00 target price on Hospira, which closed yesterday at $45.61.